<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="88910">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01742052</url>
  </required_header>
  <id_info>
    <org_study_id>MT-1303-E04</org_study_id>
    <nct_id>NCT01742052</nct_id>
  </id_info>
  <brief_title>Dose-finding Study of MT-1303</brief_title>
  <official_title>A Phase II, Multicentre, Randomised, Double-blind,Parallel Group, Placebo-controlled, Dose-finding Study to Evaluate the Safety and Efficacy of Three Different Oral Doses of MT-1303 Administered for a Period of 24 Weeks in Subjects With Relapsing-remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are:

        -  To evaluate the effects of three oral doses of MT-1303 compared to placebo given for a
           period of 24 weeks in subjects with relapsing-remitting multiple sclerosis (RRMS) on
           MRI parameters

        -  To evaluate the safety and tolerability of three oral doses of MT-1303 compared to
           placebo given for a period of 24 weeks in subjects with RRMS.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The total number of MRI Gd-enhanced T1-weighted lesions</measure>
    <time_frame>Weeks 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Relapsing-remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>MT-1303-Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-1303-Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-1303-Middle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-1303-Middle Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-1303-High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-1303-High Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-1303-Low</intervention_name>
    <arm_group_label>MT-1303-Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-1303-Middle</intervention_name>
    <arm_group_label>MT-1303-Middle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-1303-High</intervention_name>
    <arm_group_label>MT-1303-High</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RRMS as defined by the revised McDonald criteria

          -  Evidence of recent MS activity defined as either:

               -  at least one documented relapse in the previous 12 months, OR

               -  a positive gadolinium (Gd)-enhanced MRI scan within 3 months prior to screening,
                  OR

               -  at least two documented relapses in the previous 24 months with a positive
                  Gd-enhanced MRI scan within the previous 12 months

          -  Expanded Disability Status Score (EDSS) score ≥0.0 and ≤5.5 points.

        Exclusion Criteria:

          -  Primary progressive, secondary progressive or progressive relapsing MS at screening

          -  Disease duration &gt;15 years combined with an EDSS score ≤2.0

          -  Relapse of MS during the Screening Period

          -  History or known presence of other neurological disorders likely to render the
             subject unsuitable for the study

          -  History of any of a list of pre-defined cardiovascular diseases

          -  History or known presence of any significant central nervous system, infectious,
             metabolic, oncological, ophthalmological or respiratory system disease or illness
             likely to render the subject unsuitable for the study

          -  Previous exposure to any sphingosine 1-phosphate receptor modulator

          -  Receipt of a live vaccine or systemic corticosteroid use within 28 days prior to
             randomisation

          -  Previous treatment with beta-interferons or glatiramer acetate within 14 days prior
             to randomisation

          -  Previous treatment with intravenous immunoglobulin, plasmapheresis, certain
             immunosuppressants, lymphocyte-depleting therapy, total body irradiation or bone
             marrow transplantation

          -  Need, or likely need for, treatment with Class I or III anti-arrhythmic drugs or with
             heart-rate-lowering beta-blockers or calcium-channel blockers, or with any other
             drugs which can reduce the heart rate

          -  Evidence of significant anaemia, thrombocytopenia, leucopoenia or lymphocytopenia,
             renal or hepatic impairment

          -  Clinically significant electrocardiogram (ECG) findings.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vantaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kozyatagi, Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>December 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsing-remitting multiple sclerosis</keyword>
  <keyword>RRMS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
